Galectin Therapeutics Inc reported results
SEC 8-KRead source ↗
Galectin Therapeutics Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders2 buying, 6 selling6 purchases and 63 sales by directors and officers, last 12 monthsInsider trades
- Funds51 adding, 43 cuttingOf 13 active managers that changed their stake, 3 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 56% in the quarter to 2026-06-30.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Galectin Therapeutics Inc's latest figures clears our strength thresholds.
Things to watch
- Results due soon. Results are expected around 13 November; the share price can move sharply on the day.
- Volatile shares. Over the past year the shares showed annualised volatility of 90% and a beta of 0.7 against the S&P 500.
- Heavily shorted. 11.9% of the shares available to trade are sold short (35.8 days of average volume to cover).
- Missing expectations. Earnings per share fell short of the consensus estimate in 3 of the last four quarters.
Latest results
- Earnings per share
- -$0.14 against an average estimate of -$0.09: missed by 55.6%
- Share reaction
- -0.6% in the first session after the results on August 14, 2026, against -0.7% for the S&P 500
Price chart
- 1 day+0.9%
- 1 week-0.6%
- 1 month-13.8%
- This year-20.0%
- 1 year-44.0%
- 5 years+4.3%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Earnings
- Last results
- August 14, 2026
- Next results (est.)
- November 13, 2026
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Results
- Share issue
Galectin Therapeutics Inc sold unregistered shares
SEC 8-KRead source ↗
No model value for Galectin Therapeutics Inc at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.
Valuation models
We value Galectin Therapeutics Inc as an operating company, with every model that fits that kind of business. Cost of equity 8.2%: the 10-year Treasury yield (4.9%) plus a beta of 0.72 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | — | No model applies: the filings don’t yet support a value. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Galectin Therapeutics Inc with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$0.30 | +38% | — | 0% |
| Next | −$0.23 | +23% | — | 0% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is −18.9% on 90 days ago. In the last 30 days, 1 analyst raised Galectin Therapeutics Inc's forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$0.37 | −$0.33 |
| 60 days ago | −$0.37 | −$0.33 |
| 30 days ago | −$0.37 | −$0.33 |
| 7 days ago | −$0.37 | −$0.33 |
| Now | −$0.30 | −$0.23 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.09 | −$0.14 | −55.6% |
| Mar 2026 | −$0.06 | −$0.08 | −33.3% |
| Dec 2025 | −$0.10 | −$0.08 | +20.0% |
| Sept 2025 | −$0.11 | −$0.13 | −18.2% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 11.9% of tradable shares
- Days to cover
- 35.76 at average volume
- Short interest, 1 month
- −2% to October 15, 2026
- Held by institutions
- 16% of shares
- Held by insiders
- 52.8% of shares
- Employees
- 9 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| GALT | −8% | −45% | +47% | −22% | +223% | −20% |
| Industry peers (median) | −36% | −57% | −18% | −29% | −5% | −27% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| GALT | 25% | 17% | 58% | 67% | 50% | 46% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| GALT | −59% | −59% | −45% | −80% | −39% | −50% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since November 2, 2015: 91% from June 18, 2018 to December 24, 2024. Getting back needed a 991% gain, and the shares have not yet recovered.
Price behaviour
- 52-week range
- $2.08 – $6.51
- From 52-week high
- −48.8%
- vs 50-day average
- −12.5%
- vs 200-day average
- +3.8%
- Volatility (1 year)
- 90%
- Beta vs S&P 500
- 0.71
Share price after results
- Next day
- 4 up, 8 down typical move ±6.2%
- After a week
- 6 up, 6 down typical move ±11.6%
- After a month
- 7 up, 5 down typical move ±18.0%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 14, 2026 | −0.6% | −0.7% | +4.2% | +5.7% |
| May 15, 2026 | −6.8% | −1.3% | +6.4% | +12.3% |
| March 31, 2026 | +4.3% | +3.7% | −13.6% | −11.7% |
| November 14, 2025 | +8.5% | −0.9% | −3.3% | +12.1% |
| August 14, 2025 | −2.7% | −0.2% | +5.7% | +22.6% |
| May 15, 2025 | −1.5% | +1.1% | −1.5% | +14.6% |
| March 31, 2025 | −17.1% | +1.0% | −12.5% | −9.9% |
| November 14, 2024 | −4.5% | −1.9% | −6.2% | −20.3% |
| August 13, 2024 | −1.4% | +2.0% | +9.0% | +28.4% |
| May 15, 2024 | +10.6% | +1.0% | +9.5% | −7.7% |
| March 29, 2024 | +2.1% | −0.2% | +56.1% | +50.6% |
| November 13, 2023 | −13.8% | +1.8% | −11.0% | −20.5% |
Fundamentals
Who owns it
Funds buying and selling- Reported value
- $72.9M
- Institutions reporting
- 98
- Shares held vs prior quarter
- ▲ 13.2%
- Positions opened / closed
- 19 / 20
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Blackrock, Inc. | $13.9M | 3.0M | 19.0% | ▲ 273.9% |
| Vanguard Capital Management LLC | $10.1M | 2.2M | 13.8% | ▲ 10.2% |
| Geode Capital Management, LLC | $6.1M | 1.3M | 8.3% | ▲ 113.5% |
| Osaic Holdings, Inc. | $5.6M | 1.2M | 7.7% | ▲ 7.2% |
| Marshall Wace, LLP | $3.9M | 831K | 5.3% | ▼ 31.9% |
| Wealthspire Advisors, LLC | $3.3M | 722K | 4.6% | 0.0% |
| State Street Corp | $2.6M | 568K | 3.6% | ▲ 119.7% |
| Commonwealth Equity Services, LLC | $1.9M | 407K | 2.6% | ▲ 10.9% |
| Northern Trust Corp | $1.8M | 387K | 2.5% | ▲ 196.3% |
| Vanguard Fiduciary Trust Co | $1.7M | 366K | 2.3% | ▲ 20.5% |
| Vanguard Portfolio Management LLC | $1.5M | 328K | 2.1% | New |
| Two Sigma Investments, LP | $1.5M | 318K | 2.0% | ▼ 31.9% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Galectin Therapeutics Inc's complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart Insider purchases History → $64,607 6 trades by 2 insiders, last 12 months Insider sales History → $6.4M 63 trades by 6 insiders · 66% under pre-set plans
Net ▼ $6.3M net selling
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Jamil Khurram Chief Medical Officer | July 14, 2026 | Sell pre-set plan | 16,250 | $5.13 | $83,362 |
| Jamil Khurram Chief Medical Officer | June 29, 2026 | Sell pre-set plan | 47,467 | $5.04 | $239,234 |
| Shlevin Harold H. Director | June 29, 2026 | Sell pre-set plan | 22,268 | $5.04 | $112,231 |
| Jamil Khurram Chief Medical Officer | June 26, 2026 | Sell pre-set plan | 2,533 | $5.00 | $12,665 |
| Jamil Khurram Chief Medical Officer | June 26, 2026 | Sell pre-set plan | 2,037 | $5.00 | $10,185 |
| Shlevin Harold H. Director | June 26, 2026 | Sell pre-set plan | 7,732 | $5.00 | $38,660 |
| Jamil Khurram Chief Medical Officer | June 23, 2026 | Sell pre-set plan | 7,557 | $3.14 | $23,729 |
| Jamil Khurram Chief Medical Officer | May 26, 2026 | Sell pre-set plan | 568 | $3.10 | $1,761 |
| Eldred Kary Director | February 6, 2026 | Buy | 300 | $2.70 | $810 |
| Jamil Khurram Chief Medical Officer | January 6, 2026 | Sell pre-set plan | 21,446 | $3.65 | $78,278 |
| Callicutt Jack W Chief Financial Officer | January 6, 2026 | Sell pre-set plan | 20,354 | $3.67 | $74,699 |
| Lewis Joel President and CEO | January 6, 2026 | Sell pre-set plan | 37,698 | $3.58 | $134,959 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Next expected around November 13, 2026 estimated from the company's past filing pattern, not announced
- August 14, 2026
- May 15, 2026
- March 31, 2026
- November 14, 2025
- August 14, 2025
- May 15, 2025
Recent SEC filings
- DEF 14A Proxy statement
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- S-3 S-3
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Galectin Therapeutics Inc in brief
- What does Galectin Therapeutics Inc do?
- Galectin Therapeutics Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Galectin Therapeutics Inc's stock ticker?
- Galectin Therapeutics Inc trades under the ticker GALT on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Galectin Therapeutics Inc's largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Vanguard Capital Management LLC and Geode Capital Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Galectin Therapeutics Inc stock?
- Over the last 12 months, Galectin Therapeutics Inc's directors and officers reported 6 open-market purchases and 63 sales on Form 4. The insider trading page charts every trade.
- When is Galectin Therapeutics Inc's next earnings date?
- Around November 13, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Galectin Therapeutics Inc announces its own schedule.
Follow research on Galectin Therapeutics Inc
New research on the companies we cover arrives in the weekly email. Free, one email a week.